The consensus among investors is that medtech has been the best-performing part of health care for the past three to four years, and investment levels remain good. Seemingly all-encompassing of late has been companies’ preoccupation with digital strategies, but there is a lot more to this unique industry than just digital. London Technology and Life Sciences partners David Mardle and Sophie McGrath discuss their outlook and trends in the industry with In Vivo. Read the article here.